Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mesothelioma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Mesothelioma. Displaying page 6 of 6.
    « Previous 1  2  3  4  5  6 
    EudraCT Number: 2021-001417-36 Sponsor Protocol Number: BluePIPAC Start Date*: 2021-08-02
    Sponsor Name:HOSPITAL CLINICO UNIVERSITARIO
    Full Title: CLINICAL TRIAL PHASE IIB ON THE TREATMENT WITH PIPAC (PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY) IN PATIENTS WITH NON-RESECTABLE PERITONEAL CARCINOMATOSIS
    Medical condition: Patient presenting unresectable peritoneal metastases from digestive system, ovary or primary peritoneal origin
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051676 Metastases to peritoneum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002507-18 Sponsor Protocol Number: CSET2019/2955 Start Date*: 2020-04-10
    Sponsor Name:Gustave Roussy
    Full Title: Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for perito...
    Medical condition: Primary and secondary peritoneal malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068069 Peritoneal carcinomatosis LLT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004952-14 Sponsor Protocol Number: 0209-01 Start Date*: 2021-07-07
    Sponsor Name:Constellation Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors
    Medical condition: advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, ovarian clear cell cancer, endometrial carcinoma, GCB-DLBCL, small cell lu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019821-32 Sponsor Protocol Number: 20090508 Start Date*: 2010-11-04
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fa...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) PT (Completed) CZ (Prematurely Ended) SI (Completed) GR (Completed) SE (Completed) LV (Completed) EE (Completed) IT (Completed) BG (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020408-31 Sponsor Protocol Number: I2I-MC-JMMG Start Date*: 2010-11-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer
    Medical condition: • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin i...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004529-27 Sponsor Protocol Number: 1216.18 Start Date*: 2007-07-09
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EO...
    Medical condition: patients with five different tumour entities will be included in the present trial: 1. squamous cell carinoma of the head and neck 2. breast cancer 3. ovarian cancer 4. soft tissue sarcoma 5. meanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001112-53 Sponsor Protocol Number: 20101129 Start Date*: 2012-01-09
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, P...
    Medical condition: FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed) ES (Completed) BE (Completed) NL (Completed) AT (Completed) DK (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004438-25 Sponsor Protocol Number: 20060342 Start Date*: 2008-10-21
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
    Medical condition: Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cance
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017261-32 Sponsor Protocol Number: KKSH077 Start Date*: Information not available in EudraCT
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma
    Medical condition: Relapsed or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003602-16 Sponsor Protocol Number: PM1183-A-014-15 Start Date*: 2022-02-24
    Sponsor Name:Pharma Mar S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004272-20 Sponsor Protocol Number: E7389-E044-207 Start Date*: 2006-10-23
    Sponsor Name:Eisai Limited
    Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27)
    Medical condition: Advanced and/or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000415-23 Sponsor Protocol Number: PM14-A-002-20 Start Date*: 2021-05-25
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004168-30 Sponsor Protocol Number: STS001 Start Date*: 2012-08-07
    Sponsor Name:Hannover Medical School
    Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
    Medical condition: Metastatic or advanced soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004750-15 Sponsor Protocol Number: AIO-STS-0415 Start Date*: 2017-10-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
    Medical condition: advanced or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000449-21 Sponsor Protocol Number: CLAG525X2101C Start Date*: 2015-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004246-11 Sponsor Protocol Number: EDO-S101-1002 Start Date*: 2021-09-30
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad...
    Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.0 100000004864 10014735 Endometrial cancer NOS LLT
    20.0 100000004864 10002479 Angiosarcoma NOS LLT
    21.1 100000004864 10057043 Dermatofibrosarcoma LLT
    21.1 100000004864 10015103 Epithelioid sarcoma NOS LLT
    20.0 100000004864 10024193 Leiomyosarcoma NOS LLT
    20.0 100000004864 10024631 Liposarcoma NOS LLT
    22.1 100000004864 10082807 Solitary fibrous tumor LLT
    20.0 100000004864 10042866 Synovial sarcoma NOS LLT
    21.1 100000004864 10025556 Malignant fibrous histiocytoma NOS LLT
    20.0 100000004864 10029276 Neurofibrosarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003239-38 Sponsor Protocol Number: PH-L19TNFDOX2-03/16 Start Date*: 2017-07-28
    Sponsor Name:Philogen S.p.A.
    Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien...
    Medical condition: Unresectable or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000177-31 Sponsor Protocol Number: CAN-004AB Start Date*: 2012-10-18
    Sponsor Name:Prima BioMed Ltd
    Full Title: CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treat...
    Medical condition: Maintenance Treatment in [A] Patients with Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-Line Chemotherapy and [B] Patients with EOC in Second Remission
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) BE (Completed) LV (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:42:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA